NDAORALSUSPENSION
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
KATERZIA (amlodipine) by R-Pharm US is (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Approved for hypertension, myocardial ischemia, left ventricular hypertrophy. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KATERZIA is an oral amlodipine suspension formulation, a calcium channel antagonist approved in 2019 for hypertension and myocardial ischemia. It works by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle cells, reducing peripheral vascular resistance and blood pressure while improving coronary blood flow in both exertional and vasospastic angina.
$0.001BPart D
Peak12.9 years to LOEKATERZIA is at peak lifecycle with minimal Part D presence ($1M), suggesting a niche positioning within the mature amlodipine market with limited team expansion.
Mechanism of Action
(calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac…
Indications (3)
Worked on KATERZIA at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.